Another protein ANXA1 (downregulated in MC7 and BT20 E2 treated and WWOX-depleted cells) which was previously reported to regulate EMT and is associated with highly invasive basal-like breast cancer phenotype (Graauw et al. 2010) was found also to contribute to trastuzumab resistance through AKT activation (Berns et al. 2016; Sonnenblick et al. 2015). Here, ANXA1 is linked to breast carcinoma.